IMRT Series


Author

Lee et al.

Wolden et al.

Kam et al.

Kwong et al.

Tham et al.

Lee et al.

Peponi et al.

Own data

Year

2002

2006

2004

2006

2009

2009

2010

2012

Institution

UCSF

MSKCC

PWH

QMH

NCC

RTOG0225

USZ

DKFZ

Region

USA

USA

Hongkong

Hongkong

Singapore

USA

Switzerland

Germany

n

67

74

63

50

195

68

39

49

f/u

31

35

29

25

27

31

30

48

Stage III/IV

70%

77%

57%

100%

56%

59%

85%

72%

sim. CHT

75%

93%

25%

68%

57%

83%

97%

100%

adj. CHT

75%

93%

0%

68%

35%

83%

97%

0%

TD

6570

70

66

76

70

70

6670

6670,4

SD

2,122,25

2,34 o. CB

2

2,17

2,02,12

2,12

2,02,2

2,2

add. Boosts

Br 40%

CB 80%

Br/3D 56%

none

Br 10%

none

none

none

LC (year)

96% (4y)

91% (3y)

92% (3y)

96% (2y)

90% (3y)

93% (2y)

86% (3y)

90% (5y)

RC (year)

98% (4y)

93% (3y)

98% (3y)

n.r.

n.r.

91% (2y)

89% (3y)

98% (5y)

DC (year)

66% (4y)

78% (3y)

79% (3y)

94% (2y)

89% (3y)

85% (2y)

85% (3y)

86% (5y)

OS (year)

88% (4y)

83% (3y)

90% (3y)

92% (2y)

94% (3y)

80% (2y)

85% (3y)

79% (5y)

 n: number of patients, f/u: median follow up (months), sim.: simultaneous, adj.: adjuvant, CHT: chemotherapy, TD: total dose, SD: single dose, add.: additional, LC: local control, RC: regional control, DC: distant control, OS: overall survival, y: year, Br: Brachytherapy boost, CB: concomitant boost, 3D: 3dconfomal boost, nr : not reported, UCSF: University of California San Francisco [12], MSKCC: Memorial SloanKettering Cancer Center [11], PWH: Prince of Wales Hospital [14], QMH: Queen Mary Hospital [13], NCC: National Cancer Center [21], RTOG: Radiation Therapy Oncology Group [22], USZ: Universitätsspital Zürich (University Hospital Zuerich) [23], DKFZ: Deutsches Krebsforschungszentrum (German Cancer Research Center).